Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients,

Craig S Sauter; Esperanza B Papadopoulos; Miguel-Angel Perales; Ann A Jakubowski; Jenna D Goldberg; Guenther Koehne; Lauren Lechner; Craig H. Moskowitz; Sergio Giralt; Juliet N Barker; Hugo Castro-Malaspina

Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients,

Craig S Sauter, Esperanza B Papadopoulos, Miguel-Angel Perales, Ann A Jakubowski, Jenna D Goldberg, Guenther Koehne, Lauren Lechner, Craig H. Moskowitz, Sergio Giralt, Juliet N Barker, Hugo Castro-Malaspina

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 18 2011
Event	Blood - Duration: Jan 1 2020 → …

Conference

Conference	Blood
Period	1/1/20 → …

Disciplines

Medicine and Health Sciences
Immunology and Infectious Disease

Cite this

Sauter, C. S., Papadopoulos, E. B., Perales, M.-A., Jakubowski, A. A., Goldberg, J. D., Koehne, G., Lechner, L., Moskowitz, C. H., Giralt, S., Barker, J. N., & Castro-Malaspina, H. (2011). Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients,. Blood.

Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients, / Sauter, Craig S; Papadopoulos, Esperanza B; Perales, Miguel-Angel et al.
2011. Blood.

Research output: Contribution to conference › Presentation

Sauter, CS, Papadopoulos, EB, Perales, M-A, Jakubowski, AA, Goldberg, JD, Koehne, G, Lechner, L, Moskowitz, CH, Giralt, S, Barker, JN & Castro-Malaspina, H 2011, 'Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients,', Blood, 1/1/20.

@conference{f46356a093114fb9a6c10359ce7d3525,

title = "Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients,",

author = "Sauter, {Craig S} and Papadopoulos, {Esperanza B} and Miguel-Angel Perales and Jakubowski, {Ann A} and Goldberg, {Jenna D} and Guenther Koehne and Lauren Lechner and Moskowitz, {Craig H.} and Sergio Giralt and Barker, {Juliet N} and Hugo Castro-Malaspina",

note = "Abstract 4160 Background: Allogeneic stem cell transplantation (allo-SCT) remains the only curative therapy for patients with indolent B cell Non-Hodgkin's Lymphoma (B-NHL) as well as patients with aggressive B-NHL that have failed prior autologous stem cell transplants (ASCT). Myeloablative conditioning is associated with a high incidence of early transplant related mortality (TRM) particularly in patients with extensive prior therapy and advanced age.; Blood ; Conference date: 01-01-2020",

year = "2011",

month = nov,

day = "18",

language = "American English",

}

TY - CONF

T1 - Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients,

AU - Sauter, Craig S

AU - Papadopoulos, Esperanza B

AU - Perales, Miguel-Angel

AU - Jakubowski, Ann A

AU - Goldberg, Jenna D

AU - Koehne, Guenther

AU - Lechner, Lauren

AU - Moskowitz, Craig H.

AU - Giralt, Sergio

AU - Barker, Juliet N

AU - Castro-Malaspina, Hugo

N1 - Abstract 4160 Background: Allogeneic stem cell transplantation (allo-SCT) remains the only curative therapy for patients with indolent B cell Non-Hodgkin's Lymphoma (B-NHL) as well as patients with aggressive B-NHL that have failed prior autologous stem cell transplants (ASCT). Myeloablative conditioning is associated with a high incidence of early transplant related mortality (TRM) particularly in patients with extensive prior therapy and advanced age.

PY - 2011/11/18

Y1 - 2011/11/18

UR - http://www.bloodjournal.org/content/118/21/4160?sso-checked=true

M3 - Presentation

T2 - Blood

Y2 - 1 January 2020

ER -

Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients,

Conference

Disciplines

Other files and links

Cite this